Key statistics
On Tuesday, Myriad Genetics Inc (MYGN:NSQ) closed at 5.53, 45.07% above the 52 week low of 3.81 set on May 15, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 5.26 |
---|---|
High | 5.74 |
Low | 5.23 |
Bid | 5.35 |
Offer | 5.53 |
Previous close | 5.31 |
Average volume | 1.59m |
---|---|
Shares outstanding | 92.18m |
Free float | 89.20m |
P/E (TTM) | -- |
Market cap | 489.46m USD |
EPS (TTM) | -1.12 USD |
Data delayed at least 15 minutes, as of Jul 01 2025 21:00 BST.
More ▼
- Myriad Genetics Announces Early Access to the FirstGene Multiple Prenatal Screen
- Myriad Genetics Shares New Clinical Data Demonstrating Sensitivity of Precise MRD Across Multiple Cancer Types
- Myriad Genetics Highlights New Research Advancements and Oncology Innovations at 2025 ASCO Annual Meeting
- Updated: Myriad Genetics to Participate in Two Upcoming Investor Healthcare Conferences
- Myriad Genetics Announces RiskScore Study Published in JCO Precision Oncology
- Myriad Genetics Reports First Quarter 2025 Financial Results; Updates 2025 Financial Guidance
- Concerns about Mental Health Medication Side Effects Remain a Barrier to Getting Help for Those Diagnosed with Depression and Anxiety, According to the GeneSight Mental Health Monitor
- Myriad Genetics to Release First Quarter 2025 Financial Results on May 6, 2025
- Myriad Genetics Highlights MRD Clinical Validity Data at American Association for Cancer Research Annual Meeting
- Myriad Genetics Announces Study Results Show Patients with Depression had Fewer Psychiatric Hospitalizations after GeneSight Testing
More ▼